Erik Lerkevang Grove

Erik Lerkevang Grove

Auto-generated profile, based on publicly available information

Erik Lerkevang Grove

Department of Cardiology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
TTTroels Thim
Troels Thim
NKNiels Henrik Vinther Krarup
Niels Henrik Vinther Krarup
EGErik Lerkevang Grove
Erik Lerkevang Grove
CRClaus Valter Rohde
Claus Valter Rohde
BLBo Løfgren
Bo Løfgren
The Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach is applicable in all clinical emergencies for immediate assessment and treatment. The approach is widely accepted by experts in emergency medicine and likely improves outcomes by helping health care professionals focusing on the most life-threatening clinical problems. In an acute setting, high-quality ABCDE skills among all treating team members can save valuable time and improve team performance. Dissemination of knowledge and skills related to the ABCDE approach are therefore needed. This paper offers a practical “how-to” description of the ABCDE approach.

20 February 2013 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SAStefan Agewall
Stefan Agewall
MCMarco Cattaneo
Marco Cattaneo
JCJ.P. Collet
J.P. Collet
FAF. Andreotti
F. Andreotti
GLG.Y.H. Lip
G.Y.H. Lip
OTon behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis
on behalf of ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis
The ESC NSTEMI and STEMI guidelines1,2 and an ACCF/ACG/AHA consensus document3 recommend treatment with proton pump inhibitors (PPIs) in patients treated with dual antiplatelet treatment (DAPT) during the initial phase of an acute coronary syndrome (ACS) (ESC Class 1A recommendation), particularly in patients with a history of GI bleeding or peptic ulcer. Several studies have raised concerns that many PPIs, especially omeprazole, might diminish the antiplatelet effects of clopidogrel, most likely through inhibition of CYP2C19 and, consequently, the conversion of clopidogrel into its active metabolite.4,5

11 May 2011 in BMJ
Verified
Journal Article
Open access
PDF file
MCMette Charlot
Mette Charlot
EGErik L Grove
Erik L Grove
PHPeter Riis Hansen
Peter Riis Hansen
JOJonas B Olesen
Jonas B Olesen
OAOle Ahlehoff
Ole Ahlehoff
GGGunnar H Gislason
Gunnar H Gislason
Objective To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction. Design Retrospective nationwide propensity score matched study based on administrative data. Setting All hospitals in Denmark. Participants All aspirin treated patients surviving 30 days after a first myocardial infarction from 1997 to 2006, with follow-up for one year. Patients treated with clopidogrel were excluded. Main outcome measures The risk of the combined end point of cardiovascular death, myocardial infarction, or stroke associated with use of proton pump inhibitors was analysed using Kaplan-Meier analysis, Cox proportional hazard models, and propensity score matched Cox proportional hazard models. Results 3366 of 19 925 (16.9%) aspirin treated patients experienced recurrent myocardial infarction, stroke, or cardiovascular death. The hazard ratio for the combined end point in patients receiving proton pump inhibitors based on the time dependent Cox proportional hazard model was 1.46 (1.33 to 1.61; P<0.001) and for the propensity score matched model based on 8318 patients it was 1.61 (1.45 to 1.79; P<0.001). A sensitivity analysis showed no increase in risk related to use of H2 receptor blockers (1.04, 0.79 to 1.38; P=0.78). Conclusion In aspirin treated patients with first time myocardial infarction, treatment with proton pump inhibitors was associated with an increased risk of adverse cardiovascular events.

1 January 2009 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
AHAnne-Mette Hvas
Anne-Mette Hvas
SKSteen Dalby Kristensen
Steen Dalby Kristensen
EGErik Lerkevang Grove
Erik Lerkevang Grove
Summary: Platelets newly released from the bone marrow are RNA-containing and more haemostatically active than mature platelets. Immature platelets are reliably quantified by flow cytometry, and the immature platelet fraction (IPF) reflects platelet production and the rate of platelet turnover. It was the objective of this study to evaluate the presence of immature platelets in healthy subjects, patients with stable coronary artery disease (CAD) and patients with acute coronary syndromes. Flow cytometric determination of immature platelets was performed with an automated analyzer (Sysmex XE-2100) using RNA fluorescent dyes. IPF was determined in 420 individuals: 22 healthy subjects, 39 patients with stable CAD, 182 patients with unstable angina/ non-ST-segment elevation myocardial infarction (non-STEMI) and 177 patients with acute STEMI. The geometric mean [95% confidence interval] of IPF was 2.51 [2.04–3.10] in healthy subjects, 2.87 [2.45–3.36] in CAD patients, 2.93 [2.72–3.15] in the non-STEMI/unstable angina group and 3.71 [3.45–3.99] in patients with STEMI (ANOVA: p < 0.0001). This difference remained significant after adjusting for baseline characteristics (p = 0.0003). In active smokers, IPF was 18% higher than in non-smoking individuals (p = 0.007), and IPF was 16% higher in diabetics compared with non-diabetics (p = 0.060). In conclusion, the fraction of immature platelets is increased in acute coronary syndromes, especially in the acute phase of STEMI. Immature platelets with an increased haemostatic potential may contribute to coronary thrombus formation.

18 September 2012 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
JMJohn F. Martin
John F. Martin
SKSteen D. Kristensen
Steen D. Kristensen
AMAnthony Mathur
Anthony Mathur
EGErik L. Grove
Erik L. Grove
FCFizzah A. Choudry
Fizzah A. Choudry

5 April 2021 in European Heart Journal
Verified
Journal Article
Closed access
JBJurriën ten Berg
Jurriën ten Berg
DSDirk Sibbing
Dirk Sibbing
BRBianca Rocca
Bianca Rocca
EBEric Van Belle
Eric Van Belle
BCBernard Chevalier
Bernard Chevalier
JMJulinda Mehilli
Julinda Mehilli
Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.